WP
BBOT

Woodline Partners’s BridgeBio Oncology BBOT Stock Holding History

Woodline Partners’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-103,707
Closed -$928K – 1165
2026
Q1 		$928K Hold
103,707
– – ﹤0.01% 895
2025
Q4 		$1.3M Hold
103,707
– – 0.01% 819
2025
Q3 		$1.2M Buy
103,707
+460
+0.4% +$4.79K 0.01% 788
2025
Q2 		$1.1M Hold
103,247
– – 0.01% 796
2025
Q1 		$1.17M Hold
103,247
– – 0.01% 750
2024
Q4 		$1.08M Hold
103,247
– – 0.01% 745
2024
Q3 		$1.08M Hold
103,247
– – 0.01% 505
2024
Q2 		$1.06M Sell
103,247
-3,458
-3% -$35.6K 0.01% 459
2024
Q1 		$1.11M Buy
+106,705
New +$1.1M 0.01% 456

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Woodline Partners's BBOT Position: Q2 2026 in Review

Woodline Partners sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 103,707 shares — an estimated $928K sold.

Woodline Partners first reported a position in BBOT in Q1 2024 and held it in 9 quarters. The position peaked at $1.3M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Woodline Partners reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 103,707 BridgeBio Oncology shares in Q2 2026, an estimated $928K.
  • Woodline Partners first reported a position in BridgeBio Oncology in Q1 2024 and held it in 9 quarters.
  • Woodline Partners's BridgeBio Oncology position peaked at $1.3M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.